Impact of systemic lupus erythematosus on the 5-year survival of critically ill septic patients

Table 3 Crude and adjusted hazard ratios for the association between variable and the risk for 5-year mortality among 2565 enrolled subjects including SLE and matched non-SLE control subjects

	Univariable	Model-1	Model-2	Model-3	Model-4
	Crude Hrs	Adjusted Hrs	Adjusted Hrs	Adjusted Hrs	Adjusted Hrs
SLE (non-SLE as reference)	2.27 (2.01–2.57)	2.20 (1.94–2.49)	2.21 (1.95–2.50)	2.01 (1.77–2.27)	1.47 (1.22–1.77)
Age, (per 1 year increment)	1.03 (1.02–1.03)	1.03 (1.02–1.03)	1.03 (1.02–1.03)	1.02 (1.01–1.02)	1.02 (1.02–1.02)
Gender (male)	1.38 (1.19–1.61)	1.24 (1.07–1.45)	1.23 (1.06–1.44)	1.14 (0.98–1.33)	1.11 (0.95–1.30)
Urbanisation levels
Urban	Ref.		Ref.	Ref.	Ref.
Suburban	1.01 (0.88–1.17)		1.06 (0.92–1.22)	1.09 (0.94–1.25)	1.11 (0.96–1.28)
Rural	0.97 (0.83–1.14)		0.89 (0.76–1.05)	0.92 (0.78–1.07)	0.94 (0.80–1.11)
Low insured income^a	1.01 (0.90–1.13)		1.09 (0.97–1.22)	1.06 (0.95–1.19)	1.08 (0.97–1.21)
CCI > 3 (0-3 as reference)	3.06 (2.72–3.43)			2.27 (2.01–2.57)	2.23 (1.97–2.53)
Recent hospitalised infection^b	2.04 (1.75–2.38)			1.35 (1.13–1.60)	1.33 (1.12–1.59)
Medications
Glucocorticoid dosage group^c
0 mg/day	Ref.				Ref.
0-5 mg/day	1.62 (1.31–2.00)				1.18 (0.95–1.46)
≥ 5 mg/day	2.63 (2.17–3.18)				1.55 (1.27–1.90)
DMARD
Methotrexate	2.55 (1.91–3.39)				2.19 (1.61–2.99)
Sulfasalazine	1.68 (1.03–2.75)				0.84 (0.50–1.42)
Hydroxychloroquine	2.04 (1.78–2.35)				0.98 (0.80–1.19)
Immunosuppressants^d	2.14 (1.87–2.45)				1.45 (1.22–1.74)

^aInsured income lower than median income (21,900 New Taiwan dollars). ^bWithin 3 months prior to index admission. ^cPrednisolone equivalent. ^dCyclophosphamide, azathioprine, cyclosporine, mycophenolate, and mycophenolic. Abbreviations: SLE Systemic lupus erythematosus, CCI Charlson comorbidity index, DMARD Disease-modifying antirheumatic drug

ISSN: 1478-6362